This article discusses how the marketing of controversial drugs in developing countries demonstrates the power and priorities of the pharmaceutical industry. Example highlighted: Estrogen-Progesterone combination drugs.
This article discusses how the marketing of controversial drugs in developing countries demonstrates the power and priorities of the pharmaceutical industry. Example highlighted: Estrogen-Progesterone combination drugs.
Links:
[1] http://www.cwhn.ca/en/taxonomy/term/3031
[2] http://www.cwhn.ca/en/taxonomy/term/5498
[3] http://www.cwhn.ca/en/taxonomy/term/4180
[4] http://www.cwhn.ca/en/taxonomy/term/5697
[5] http://www.cwhn.ca/en/taxonomy/term/3547
[6] http://www.cwhn.ca/en/taxonomy/term/3663
[7] http://www.cwhn.ca/en/taxonomy/term/3021
[8] http://www.cwhn.ca/en/taxonomy/term/3661
[9] http://www.cwhn.ca/en/taxonomy/term/4147
[10] http://www.cwhn.ca/en/taxonomy/term/6119
[11] http://www.cwhn.ca/en/taxonomy/term/3899
[12] http://www.cwhn.ca/en/taxonomy/term/6124
[13] http://www.cwhn.ca/print/46444
[14] http://www.cwhn.ca/en/node/15818
[15] http://www.cwhn.ca/sites/default/files/PDF/Healthsharing/1986_Healthsharing_Vol_7_No_4_Fall.pdf